Please login to the form below

Not currently logged in
Email:
Password:

MRSA

This page shows the latest MRSA news and features for those working in and with pharma, biotech and healthcare.

Motif Bio preps US filing after antibiotic clears phase III

Motif Bio preps US filing after antibiotic clears phase III

resistance to other antibiotics, including ‘superbugs’ such as methicillin resistant Staphylococcus aureus (MRSA).

Latest news

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    In 2011 AZ launched novel cephalosporin Zinforo (ceftaroline fosamil), the first drug in the class to be approved with data showing it could tackle the superbug methicillin-resistant Staphylococcus aureus (MRSA).

  • Pfizer takes MRSA vaccine into phase IIb trial Pfizer takes MRSA vaccine into phase IIb trial

    Trial will involve patients undergoing elective spinal fusion surgery.  . Pfizer has started enrolling patients into a mid-stage trial of its candidate vaccine for 'superbug' methicillin-resistant Staphylococcus aureus (MRSA). ... The company is trying

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    It is a broad-spectrum antibiotic and can be used to treat infections caused both Gram- positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas species. ... Treatment failure rates in pneumonia,

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    Sivextro is in the oxazolidinone class of antibiotics has been approved to treat ABSSSIs caused by certain Gram-positive bacteria, including 'superbug' methicillin-resistant Staphylococcus aureus (MRSA), and is available in ... Until the approval of

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    In November 2013, it won priority review from the US FDA for acute bacterial SSSIs caused by susceptible Gram-positive bacteria (including MRSA). ... Dalbavancin has an improved dosing regimen and increased potency versus vancomycin against Gram-positive

More from news
Approximately 4 fully matching, plus 76 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics